SAB Biotherapeutics, Inc.
General ticker "SABS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $26.5M (TTM average)
SAB Biotherapeutics, Inc. follows the US Stock Market performance with the rate: 41.8%.
Estimated limits based on current volatility of 2.4%: low 3.42$, high 3.58$
Factors to consider:
- Total employees count: 57 as of 2023
- Top business risk factors: Economic downturns and volatility, Regulatory and compliance, Market competition, Manufacturing scale up, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.38$, 5.93$]
- 2026-12-31 to 2027-12-31 estimated range: [1.99$, 5.06$]
Financial Metrics affecting the SABS estimates:
- Positive: with PPE of -1.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Return on assets ratio (scaled to [-100,100]) of 7.13 > 6.06
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 87.67 > 64.29
Short-term SABS quotes
Long-term SABS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2.24MM | $1.32MM | $0.00MM |
| Operating Expenses | $40.31MM | $44.23MM | $48.95MM |
| Operating Income | $-38.08MM | $-42.91MM | $-48.95MM |
| Non-Operating Income | $-4.12MM | $8.81MM | $62.23MM |
| Interest Expense | $0.32MM | $0.32MM | $0.24MM |
| R&D Expense | $16.52MM | $30.25MM | $34.35MM |
| Income(Loss) | $-42.19MM | $-34.11MM | $13.27MM |
| Net Income(Loss)* | $-42.19MM | $-34.11MM | $13.27MM |
| Stockholders Equity | $57.30MM | $25.97MM | $151.49MM |
| Assets | $83.94MM | $44.20MM | $172.81MM |
| Operating Cash Flow | $-25.12MM | $-34.29MM | $-44.78MM |
| Capital expenditure | $0.20MM | $0.34MM | $0.93MM |
| Investing Cash Flow | $-0.15MM | $-11.96MM | $-121.71MM |
| Financing Cash Flow | $66.77MM | $-1.17MM | $168.30MM |
| Earnings Per Share** | $-7.64 | $-3.68 | $0.69 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.